Trial Profile
A Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765(Ibrutinib), in Relapsed and Refractory Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) and B-cell Prolymphocytic Leukemia (B-PLL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 09 Feb 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 01 Nov 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 27 Jun 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.